Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis:: A prospective randomized double-blind trial

被引:54
作者
Gottrand, F
Kalach, N
Spyckerelle, C
Guimber, D
Mougenot, JF
Tounian, P
Lenaerts, C
Roquelaure, B
Lachaux, A
Morali, A
Dupont, C
Maurage, C
Husson, MO
Barthelemy, P
机构
[1] Labs AstraZeneca France, Rueil Malmaison, France
[2] Clocheville Hosp, Tours, France
[3] Childrens Hosp, Vandoeuvre Les Nancy, France
[4] Hop Edouard Herriot, Lyon, France
[5] Hop Enfants La Timone, Marseille, France
[6] Hop St Vincent de Paul, Amiens, France
[7] Trosseau Hosp, Paris, France
[8] Calmette Hosp, Dept Microbiol, Lille, France
[9] Hop St Antoine, Dept Pediat, Lille, France
[10] Hop Robert Debre, F-75019 Paris, France
[11] Calmette Hosp, Dept Microbiol, Creil, France
关键词
D O I
10.1067/mpd.2001.118197
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives: The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) For the treatment of Helicobacter pylori gastritis in children. Study design: Seventy-three children with dyspeptic symptoms were included in the trial (mean age 10.8 years; range, 3.3 to 15.4). Patients were randomized to receive OAC or amoxicillin and clarithromycin (AC) for 7 days. H pylori status was assessed before and 4 weeks after eradication treatment, by use of the carbon 13-labeled urea breath test. Results: In intent-to-treat analysis (n = 63), eradication rates were 74.2% (95% CI, 58.7 to 89.6) in the OAC group and 9.4% (95% CI, 0 to 19.5) in the AC group. In per-protocol analysis (n = 53), the eradication rate increased to 80% (95% CI, 64.3 to 95.7), remaining significantly higher than in AC group (10.7%; 95% CI, 0 to 22.2). Resistance of strains to clarithromycin was rare (3/39 = 7.7%) and was not associated with failure of treatment. Adverse events were reported in 24.6% of patients and remained mild. Conclusion: This study shows that 1-week OAC triple therapy results in successful eradication of H pylori in 75% of children with gastritis.
引用
收藏
页码:664 / 668
页数:5
相关论文
共 22 条
[1]   Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia [J].
Blum, AL ;
Talley, NJ ;
O'Moráin, C ;
van Zanten, SV ;
Labenz, J ;
Stolte, M ;
Louw, JA ;
Stubberöd, A ;
Theodórs, A ;
Sundin, M ;
Bolling-Sternevald, E ;
Junghard, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1875-1881
[2]  
Broutet N, 1998, GASTROENTEROLOGY, V114, pA81
[3]   One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection [J].
Casswall, TH ;
Alfven, G ;
Drapinski, M ;
Bergstrom, M ;
Dahlstrom, KA .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1998, 27 (04) :415-418
[4]   In-vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children [J].
Dhaenens, L ;
Szczebara, F ;
Husson, MO .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (02) :318-319
[5]  
Dohil R, 1997, AM J GASTROENTEROL, V92, P244
[6]   Current therapy for Helicobacter pylori infection in children and adolescents [J].
Gold, BD .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 13 (07) :571-579
[7]   Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children [J].
Kato, S ;
Ritsuno, H ;
Ohnuma, K ;
Iinuma, K ;
Sugiyama, T ;
Asaka, M .
HELICOBACTER, 1998, 3 (04) :278-282
[8]  
Lamouliatte H, 1998, GASTROENTEROLOGY, V114, pA194
[9]   The MACH2 study:: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies [J].
Lind, T ;
Mégraud, F ;
Unge, P ;
Bayerdörffer, E ;
O'Morain, C ;
Spiller, R ;
van Zanten, SV ;
Bardhan, KD ;
Hellblom, M ;
Wrangstadh, M ;
Zeijlon, L ;
Cederberg, C .
GASTROENTEROLOGY, 1999, 116 (02) :248-253
[10]   Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial:: the MACH 2 study [J].
Mégraud, F ;
Lehn, N ;
Lind, T ;
Bayerdörffer, E ;
O'Morain, C ;
Spiller, R ;
Unge, P ;
Van Zanten, SV ;
Wrangstadh, M ;
Burman, CF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2747-2752